Determinants of the Sensorineural Hearing Loss in Patients with Multidrug-Resistant Tuberculosis in Kinshasa (Democratic Republic of the Congo): A Prospective Cohort Study
Background: The onset of the hearing loss is a major challenge during the treatment of multidrug-resistant tuberculosis (MDR-TB). Aminoglycoside-based regimens, to a lesser extent based on bedaquiline, induce ototoxic sensorineural hearing loss. Research on risk factors is essential to enable high-risk individuals to benefit from preventive measures in settings with limited resources. Objective: This study aimed to assess the determinants of the hearing loss in patients with MDR-TB. Methods: This prospective multicenter cohort study included 337 patients with MDR-TB. It was performed in Kinshasa (Democratic Republic of the Congo) between January 2020 and January 2021. Sociodemographic, clinical, biological, therapeutic, and audiometric data were exported and analyzed using Stata 17 and MedCalc. The fixed-effect linear regression panel model was used to assess the degree of the hearing loss over time according to the following covariates: therapeutic regimen (aminoglycosides, bedaquiline, or alternate), stage of chronic kidney disease (CKD), age at inclusion, body mass index, serum albumin level, HIV status, alcohol intake, hypertension, and hemoglobin level. The Hausman test was used to select between fixed- and random-effect estimators. The threshold for statistical significance was set at p < 0.05. Result: A total of 236 patients (70%) received an aminoglycoside-based regimen, 61 (18%) received a bedaquiline-based regimen, and 40 (12%) received aminoglycosides relayed by bedaquiline. The frequency of the hearing loss increased from 62% to 96.3% within six months for all therapeutic regimens. The Hearing loss worsened, with moderate (72.4%) and profound (16%) deafness being predominant. An Exposure to the treatment for more than one month (β coeff: 27.695, Se: 0.793, p < 0.001), AG-based regimen, age ≥ 40 years (β coeff: 6.102, Se: 1.779, p < 0.001), hypoalbuminemia (β coeff: 5.610, Se: 1.682, p = 0.001), and an eGFR < 60 mL/min/1.73m2 (β coeff: 6.730, Se: 2.70, p = 0.013) were the independent risk factors associated with the hearing loss in patients with MDR-TB. Conclusions: The Hearing loss was more prevalent and worsened during the treatment of the patients with MDR-TB. An Exposure for more than one month, AG-based regimens, advanced age, hypoalbuminemia, and CKD have emerged as the main determinants of the worsening of the hearing loss.
References
[1]
World Health Organization (2019) Global Tuberculosis Report 2019. Geneva. https://www.who.int/publications/i/item/9789241565714
[2]
Kashongwe, I., Anshambi, N, Maingowa, N, Aloni, M, Kaswa, M, Kayembe, J.M, et al. (2020) Use of Bedaquiline as Replacement for Aminoglycosides in the Shorter Regimen for Multidrug-Resistant Tuberculosis Patients with Hearing Loss: A Report of 39 Cases in Kinshasa, Democratic Republic of the Congo. Journal of Pulmonary & Respiratory Medicine, 10, 1-6.
[3]
Kashongwe, I., Mbulula, L., Mawete, F., Anshambi, N., Maingowa, N., Kaswa, M., et al. (2020) Implementing a Short Regimen for Multidrug-Resistant Tuberculosis in Kinshasa, Democratic Republic of Congo: A Cohort Study 2014-2017. Journal of Tuberculosis Research, 8, 111-126. https://doi.org/10.4236/jtr.2020.83010
[4]
Trébbucq, A., Schwoelbel, V. and Kashogwe, Z. (2018) Treatment Outcome with a Short Multidrug-Resistant Tuberculosis Regimen in Nine African Countries. The International Journal of Tuberculosis and Lung Disease, 22, 17-25. https://doi.org/10.5588/ijtld.17.0498
[5]
World Health Organization (2020) WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment: Drug-Resistant Tuberculosis Treatment. https://iris.who.int/bitstream/handle/10665/332397/9789240007048
[6]
Mpwate, M., Mbambu, E., Matanda, C., Lema, G., Kaswa, M., Aloni, M., et al. (2023) Sensorineural Hearing Loss in Multidrug-Resistant Tuberculosis Patients in Kinshasa (Democratic Republic of Congo): Prospective Cohort Study of Therapeutic Regimen with Aminoglycoside versus Bedaquiline. Journal of Tuberculosis Research, 11, 109-119. https://doi.org/10.4236/jtr.2023.113011
[7]
World Health Organization (2023) Deafness and Hearing Loss. https://www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss
[8]
Chadha, S., Kamenov, K. and Cieza, A. (2021) The World Report on Hearing, 2021. Bull World Health Organ, 99, 242-242A.
[9]
Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo, J.L., et al. (2003) Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42, 1206-1252
World health Organization (2015) Obesity and Overweight. https://www.who.int/fr/news-room/fact-sheets/detail/obesity-and-overweight
[12]
Babor, T.F, Higgins-Biddle, J.C, Saunders, J.B. and Monteiro M.G. (2001) AUDIT: The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Care. 2nd Edidtion, 40 p. https://www.paho.org/sites/default/files/Auditmanual_ENG.pdf
[13]
Orth, S.R., Stockmann, A., Conradt, C., Ritz, E., Ferro, M., Kreusser, W., et al. (1998) Smoking as a Risk Factor for End-Stage Renal Failure in Men with Primary Renal Disease. Kidney International, 54, 926-931.
[14]
World Health Organization. (2011) Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. https://www.who.int/publications/i/item/WHO-NMH-NHD-MNM-11.1
[15]
Oster, H.S., Dolev, Y., Kehat, O., Weis-Meilik, A. and Mittelman, M. (2022) Serum Hypoalbuminemia Is a Long-Term Prognostic Marker in Medical Hospitalized Patients, Irrespective of the Underlying Disease. Journal of Clinical Medicine, 11, Article 1207. https://doi.org/10.3390/jcm11051207
[16]
KDIGO. (2013) Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplements, 3, 1-160.
[17]
Pujol, R., Debreuil, C.H. (1998) Les troubles d’audition chez l’adulte. SIMEP, p. 43.
[18]
Kashongwe, I., Mbulula, L., Mawete, F., Anshambi, N., Maingowa, N., Kaswa, M., et al. (2020) Implementing a Short Regimen for Multidrug-Resistant Tuberculosis in Kinshasa, Democratic Republic of Congo: A Cohort Study 2014-2017. Journal of Tuberculosis Research, 8, 111-126. https://doi.org/10.4236/jtr.2020.83010
[19]
Hong, H., Dowdy, D.W., Dooley, K.E., Francis, H.W., Budhathoki, C., Han, H.R., et al. (2020) Aminoglycoside-Induced Hearing Loss among Patients Being Treated for Drug-Resistant Tuberculosis in South Africa: A Prediction Model. Clinical Infectious Diseases, 70, 917-924. https://doi.org/10.1093/cid/ciz289
[20]
Sogebi, O.A., Adefuye, B.O., Adebola, S.O., Oladeji, S.M. and Adedeji, T.O. (2017) Clinical Predictors of Aminoglycoside-Induced Ototoxicity in Drug-Resistant Tuberculosis Patients on Intensive Therapy. AurisNasus Larynx, 44, 404-410. https://doi.org/10.1016/j.anl.2016.10.005
[21]
Henry, J.A., Roberts, L.E., Caspary, D.M., Theodoroff, S.M. and Salvi, R.J. (2014) Underlying Mechanisms of Tinnitus: Review and Clinical Implications. Journal of the American Academy of Audiology, 25, 5-22. https://doi.org/10.3766/jaaa.25.1.2
[22]
Fassad, M.R., Desouky, L.M., Asal, S. and Abdalla, E.M. (2014) Screening for the Mitochondrial A1555G Mutation among Egyptian Patients with Non-Syndromic, Sensorineural Hearing Loss. International Journal of Molecular Epidemiology and Genetics, 5, 200-204.
[23]
Sturdy, A., Goodman, A., José, R.J., Loyse, A,. O’Donoghue, M., Kon, O.M., et al. (2011) Multidrug-Resistant Tuberculosis (MDR-TB) Treatment in the UK: A Study of Injectable Use and Toxicity in Practice. Journal of Antimicrobial Chemotherapy, 66, 1815-1820. https://doi.org/10.1093/jac/dkr221
[24]
Duggal, P. and Sarkar, M. (2007) Audiologic Monitoring of Multi-Drug Resistant Tuberculosis Patients on Aminoglycoside Treatment with Long Term Follow-Up. BMC Ear, Nose and Throat Disorders, 7, Article No. 5. https://doi.org/10.1186/1472-6815-7-5
[25]
Soh, A.Z., Chee, C.B.E., Wang, Y.T., Yuan, J.M. and Koh, W.P. (2017) Alcohol Drinking and Cigarette Smoking in Relation to Risk of Active Tuberculosis: Prospective Cohort Study. BMJ Open Respiratory Research, 4, e000247. https://doi.org/10.1136/bmjresp-2017-000247
[26]
Simou, E., Britton, J. and Leonardi-Bee, J. (2018) Alcohol Consumption and Risk of Tuberculosis: A Systematic Review and Meta-Analysis. The International Journal of Tuberculosis and Lung Disease, 22, 1277-1285. https://doi.org/10.5588/ijtld.18.0092
[27]
Cormier, M., Schwartzman, K., N’Diaye, D.S., Boone, C.E., Dos Santos, A.M., Gaspar, J., et al. (2019) Proximate Determinants of Tuberculosis in Indigenous Peoples Worldwide: A Systematic Review. Lancet Glob Health, 7, e68-e80. https://doi.org/10.1016/S2214-109X(18)30435-2
[28]
Silva, D.R., Muñoz-Torrico, M., Duarte, R., Galvão, T., Bonini, E.H., Arbex, F.F., et al. (2018) Risk Factors for Tuberculosis: Diabetes, Smoking, Alcohol Use, and the Use of Other Drugs. Jornal Brasileiro de Pneumologia, 44, 145-152. https://doi.org/10.1590/s1806-37562017000000443
[29]
Lampalo, M., Jukić, I., Bingulac-Popović, J., Stanić, H.S., Barišić, B. and Popović-Grle, S. (2019) The Role of Cigarette Smoking and Alcohol Consumption in Pulmonary Tuberculosis Development and Recurrence. Acta Clinica Croatica, 58, 590-594. https://doi.org/10.20471/acc.2019.58.04.04
[30]
Wessels, J., Walsh, C.M. and Nel, M. (2019) Smoking Habits and Alcohol Use of Patients with Tuberculosis at Standerton Tuberculosis Specialised Hospital, Mpumalanga, South Africa. Health SA Gesondheid, 24, a1146. https://doi.org/10.4102/hsag.v24i0.1146
[31]
Patra, J., Jha, P., Rehm, J. and Suraweera, W. (2014) Tobacco Smoking, Alcohol Drinking, Diabetes, Low Body Mass Index and the Risk of Self-Reported Symptoms of Active Tuberculosis: Individual Participant Data (IPD) Meta-Analyses of 72,684 Individuals in 14 High Tuberculosis Burden Countries. PLOS ONE, 9, e96433. https://doi.org/10.1371/journal.pone.0096433
[32]
Torre, P., Hoffman, H.J., Springer, G., Cox, C., Young, M.A., Margolick, J.B., et al. (2015) Hearing Loss among HIV-Seropositive and HIV-Seronegative Men and Women. JAMA Otolaryngology–Head & Neck Surgery, 141, 202-210. https://doi.org/10.1001/jamaoto.2014.3302
[33]
Al-Malky, G., Dawson, S.J., Sirimanna, T., Bagkeris, E. and Suri, R. (2015) High-Frequency Audiometry Reveals High Prevalence of Aminoglycoside Ototoxicity in Children with Cystic Fibrosis. Journal of Cystic Fibrosis, 14, 248-254. https://doi.org/10.1016/j.jcf.2014.07.009
[34]
Ahmed, R.M., Hannigan, I.P., MacDougall, H.G., Chan, R.C. and Halmagyi, G.M. (2012) Gentamicin Ototoxicity: A 23-Year Selected Case Series of 103 Patients. The Medical Journal of Australia, 196, 701-704. https://doi.org/10.5694/mja11.10850
[35]
Gonzalez, L.S. and Spencer, J.P. (1998) Aminoglycosides: A Practical Review. American Family Physician, 58, 1811-1820.
[36]
Pai, M.P., Nafziger, A.N. and Bertino, J.S. (2011) Simplified Estimation of Aminoglycoside Pharmacokinetics in Underweight and Obese Adult Patients. Antimicrobial Agents and Chemotherapy, 55, 4006-4011. https://doi.org/10.1128/AAC.00174-11
[37]
Emmett, S.D., Schmitz, J., Karna, S.L., Khatry, S.K., Wu, L., LeClerq, S.C., et al. (2018) Early Childhood Undernutrition Increases Risk of Hearing Loss in Young Adulthood in Rural Nepal. The American Journal of Clinical Nutrition, 107, 268-277. https://doi.org/10.1093/ajcn/nqx022
Lesniak, W., Pecoraro, V.L. and Schacht, J. (2005) Ternary Complexes of Gentamicin with Iron and Lipid Catalyze Formation of Reactive Oxygen Species. Chemical Research in Toxicology, 18, 357-364. https://doi.org/10.1021/tx0496946
[40]
Minhas, R.S., Iyengar, D.A., Thakur, J.S. and Azad, R.K. (2018) Effect of HIV and Antiretroviral Treatment on Auditory Functions. International Archives of Otorhinolaryngology, 22, 378-381. https://doi.org/10.1055/s-0038-1639594
[41]
Harris, T., Bardien, S., Schaaf, H.S., Petersen, L., De Jong, G. and Fagan, J.J. (2012) Aminoglycoside-Induced Hearing Loss in HIV-Positive and HIV-Negative Multidrug-Resistant Tuberculosis Patients. South African Medical Journal, 102, 363-366. https://doi.org/10.7196/SAMJ.4964
[42]
de Jager, P. and van Altena, R. (2002) Hearing Loss and Nephrotoxicity in Long-Term Aminoglycoside Treatment in Patients with Tuberculosis. The International Journal of Tuberculosis and Lung Disease, 6, 622-627.
[43]
Prezant, T.R., Agapian, J.V., Bohlman, M.C., Bu, X., Oztas, S., Qiu, W.Q., et al. (1993) Mitochondrial Ribosomal RNA Mutation Associated with Both Antibiotic-Induced and Non-Syndromic Deafness. Nature Genetics, 4, 289-294. https://doi.org/10.1038/ng0793-289
[44]
Estivill, X., Govea, N., Barceló, E., Badenas, C., Romero, E., Moral, L., et al. (1998) Familial Progressive Sensorineural Deafness Is Mainly Due to the mtDNA A1555G Mutation and Is Enhanced by Treatment of Aminoglycosides. American Journal of Human Genetics, 62, 27-35. https://doi.org/10.1086/301676
[45]
Fischel-Ghodsian, N., Prezant, T.R., Bu, X. and Oztas, S. (1993) Mitochondrial Ribosomal RNA Gene Mutation in a Patient with Sporadic Aminoglycoside Ototoxicity. American Journal of Otolaryngology, 14, 399-403. https://doi.org/10.1016/0196-0709(93)90113-L
[46]
Hutchin, T., Haworth, I., Higashi, K., Fischel-Ghodsian, N., Stoneking, M., Saha, N., et al. (1993) A Molecular Basis for Human Hypersensitivity to Aminoglycoside Antibiotics. Nucleic Acids Research, 21, 4174-4179. https://doi.org/10.1093/nar/21.18.4174
